Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to NextCure, Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
8
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
NEXTCURE, INC. its own name
named as the applicant on its applications, in US
6 publishedNextCure, Inc. its own name
US, as the owner printed on each patent
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Apr 29, 2025 | 12,286,478 | B7-H4 antibodies and methods of use thereof | Pharmaceuticals | NextCure, Inc. |
| Sep 10, 2024 | 12,084,495 | Compositions and methods for modulating LAIR signal transduction | Biotechnology | NextCure, Inc. |
| Jul 19, 2022 | 11,390,675 | Antibodies for Siglec-15 and methods of use thereof | Pharmaceuticals | NextCure, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Mar 13, 2025 | 2025/0084164 | COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION | Pharmaceuticals | NEXTCURE, INC. |
| Dec 5, 2024 | 2024/0400678 | ANTIBODIES FOR SIGLEC-15 AND METHODS OF USE THEREOF TO TREAT DISUSE OSTEOPOROSIS | Pharmaceuticals | NextCure, Inc. |
| Oct 24, 2024 | 2024/0352121 | LAIR-1 AGONISTIC ANTIBODIES AND METHODS OF USE THEREOF | Pharmaceuticals | NEXTCURE, INC. |
| Nov 9, 2023 | 2023/0357384 | COMPOSITIONS AND METHODS FOR MODULATING FLRT3 MEDIATED SIGNAL TRANSDUCTION | Pharmaceuticals | NextCure, Inc. |
| Nov 25, 2021 | 2021/0363240 | COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION | Pharmaceuticals | NEXTCURE, INC. · patent 12,084,495 granted from it |
| Feb 4, 2021 | 2021/0032346 | B7-H4 ANTIBODIES AND METHODS OF USE THEREOF | Pharmaceuticals | NEXTCURE, INC. · patent 12,286,478 granted from it |
| Jan 7, 2021 | 2021/0002373 | KLRG1 Binding Compositions and Methods of Use Thereof | Biotechnology | NEXTCURE, INC. |
| Jul 4, 2019 | 2019/0202912 | ANTIBODIES FOR SIGLEC-15 AND METHODS OF USE THEREOF | Pharmaceuticals | NEXTCURE, INC. · patent 11,390,675 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.